Hummingbird and Synaffix agree to antibody-drug conjugate deal worth up to $150M

The Dutch biotech Synaffix has been active on the deal front for the past few years. And it’s not showing signs of stopping, hitting the ground running in 2023 by inking a deal with Singapore’s Hummingbird Bioscience.

In an announcement Monday, Hummingbird and the antibody-drug conjugate biotech said they will...

Click to view original post